Videos
Watch our experts break down complex topics and suggest ways to adjust your business. Gain clarity, step-by-step.
AI for Health Plans: Unlocking the Power of Clinical Data
In the first installment of our AI for health plans video series, Avalere is joined by experts Mia Bolton and Teddy Gedamu from Tenasol to discuss the regulatory and market dynamics around clinical data and what this means for health plans.
Kidney Care Agenda: Fall 2024
Ahead of the American Society of Nephrology Kidney Week, Avalere experts dive into the key regulatory and legislative developments related to kidney disease that expect to see action in the remaining weeks of 2024.
The Evolution of Lactation Care
In this installment of our women's health video series, Sarah Kellogg Neff, CEO of the Lactation Network, joins Avalere to explore the value of access to lactation services.
Innovations in Fertility and Family-Forming Care
In this installment of our women's health video series, Avalere is joined by Jessica Bell van der Wal, co-Founder and CEO of Frame Fertility, for a discussion of the myths, challenges, and future surrounding family-forming care.
The Impact of Caregiving on Mental Health
In the first installment of our women's health video series, Avalere sits down with Dr. Madhavi Vemireddy of caregiving platform Cleo to discuss the impact caregiving can have on one’s mental health.
Key NCCN Sessions Impacting Market Access to Oncology Care
In this video, Avalere market access experts discuss major takeaways from the 2024 NCCN (National Comprehensive Cancer Network) Annual Conference in the areas of reimbursement, early detection of cancer, consideration of a broader pool as provider decision makers, and patient involvement in their care decisions.
IRA Impacts on Market Access Strategy
Ahead of Asembia 2024, Avalere market access experts discuss the potential impacts of IRA provisions, including Part D redesign and Medicare drug price negotiation, on go-to-market and contracting strategy.
Discussing Value at Asembia and ISPOR
Ahead of the upcoming Asembia and ISPOR conferences, Avalere experts discuss the role of external assessors in value assessment.
Mitigating and Preventing Drug Shortages
Avalere experts provide insights on the dynamics and policy proposals surrounding recent drug shortages.
The Evolution of Value Requirements
Ahead of Asembia 2024, Avalere experts discuss the evolution of biopharmaceutical value requirements and how organizations will need to evolve their business models accordingly.
Avalere’s Insights on Rare Disease
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts summarize key learnings for pharmaceutical companies to consider.
How Policies Shape the Rare Disease Treatment Landscape
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts explore policies shaping rare disease drug development and access.
How the FDA and Market Access Impact Rare Disease Drug Access
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts dive into access drivers and considerations in the rare disease space.
Innovations in Patient-Centricity: How Rare Disease is Leading the Way
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts dive into patient centricity trends in rare disease.
How to Think About Rare Diseases in the US and Globally
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts provide an introduction into regulatory approaches to rare diseases.
Quantifying Indirect Burden and Measuring Novel Elements of Value
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #10: Quantifying Indirect Burden and Measuring Novel Elements of Value
Impacts of Inflation Reduction Act on Patient Behavior and Affordability
Avalere experts are joined by Kevin L. Hagan, President of the PAN Foundation, to discuss their findings on the impacts of the Inflation Reduction Act’s Part D benefit redesign on patient utilization and affordability.
Policy’s Pressure on HEOR
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #9: Policy’s Pressure on HEOR.
HEOR as a Differentiator Versus a Commodity
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #8: HEOR as a Differentiator Versus a Commodity.
Reevaluating Value Assessment for HEOR in 2023
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #7: Value Assessment.